ILAR Council

ILAR’s advisory body, the ILAR Council, serves four principal functions:

  • to provide program direction and strategic planning;
  • to oversee information and communication programs (e.g., the ILAR website and the quarterly ILAR Journal); 
  • to oversee studies, reports, workshops, and other projects; and 
  • to direct ILAR’s international programs. 
To fulfill ILAR’s mission, Council members serve on one of three subcommittees: the Development and Outreach Subcommittee, International Subcommittee, and ILAR Journal Editorial Board.
The ILAR Council meets for two days twice annually.


Michael D. Lairmore, Acting Chair
Professor and Dean, School of Veterinary Medicine
University of California, Davis

Karin Blumer
Scientific Affairs
Novartis International AG

Cory Brayton
Associate Professor of Molecular and Comparative Pathobiology
Johns Hopkins University

Joseph J. DeGeorge
Global Head of Safety Assessment and Laboratory Animal Resources
Merck Research Laboratories

Ron DeHaven
Executive Vice President
American Veterinary Medical Association

Lewis B. Kinter

Malak Kotb
Chair, Department of Basic Sciences
University of North Daokta

Paul A. Locke
Associate Professor
Department of Environmental Health Sciences
Johns Hopkins School of Public Health

Daniel S. Marsman
Head, Safety and Regulatory Affairs
Procter and Gamble Health Care

Melinda A. Novak
Professor of Psychology
University of Massachusetts

James A. Roth
Clarence Hartley Covault Distinguished Professor
Director, Center for Food Security and Public Health
College of Veterinary Medicine
Iowa State University

Lawrence B. Schook
Vice President for Research
Edward William and Jane Marr Gutgsell Professor
University of Illinois

Sheldon Sloan
Internal Medicine Portfolio Leader Established Products
Janssen Research and Development, LLC

Patricia Turner
Program Leader, Laboratory Animal Science
Professor, Department of Pathobiology
Ontario Veterinary College
University of Guelph

Michael D. Lairmore, Dean, oversees all School of Veterinary Medicine teaching, research and service activities, personnel, facilities and funding resources. He presides over the six academic departments, the William R. Pritchard Veterinary Medical Teaching Hospital, the California Animal Health and Food Safety Laboratory System, the Veterinary Medicine Teaching and Research Center in Tulare, Veterinary Medicine Extension and other centers of excellence. Lairmore came to UC Davis from The Ohio State University. He served as a professor and associate dean for research and graduate studies at the College of Veterinary Medicine, where he led a successful sponsored research and commercialization program. He also served as associate director of the University's Comprehensive Cancer Center. While Chair for the Department of Veterinary Biosciences, he received unanimous praise for leading his department to new heights in research funding and scholarly achievement. He is committed to finding new ways for the school and its faculty to contribute to the health of the animals and people while being good stewards of the environment and economy of California. His goals include building mission-focused programs that will continue to provide outstanding education for society-ready veterinarians and that will produce innovative research findings to address important problems, ranging from clinical veterinary medicine to public health. Lairmore earned his DVM degree from the University of Missouri at Columbia before working as a dairy and small animal veterinarian. Following practice, he completed a residency and PhD program in experimental pathology at Colorado State University at Fort Collins. He is board certified in veterinary anatomic pathology as well as veterinary virology and immunology. He is one of the few veterinarians elected as a member of the Institute of Medicine, the health arm of the National Academy of Sciences. He is also a fellow in the American Academy of Microbiology and the American Association for the Advancement of Sciences. Lairmore is a scientist who bridges multiple disciplines to address basic questions related to viral causes of cancer. His research has provided significant breakthroughs in the biology of human retroviruses and the understanding of viral-associated carcinogenesis. Lairmore has authored or co-authored more than 180 scientific publications.

Karin Blumer is Senior Manager Scientific Affairs for Novartis Switzerland and chairs the Animal Welfare Group at the EFPIA. She graduated in Veterinary Medicine with a doctorate on the ethics of animal research and also holds a philosophical PhD from the Jesuit Faculty for Philosophy in Munich.

Cory Brayton recieved her DVM from Cornell University, and did postdoctoral research and pathology training in New York City at the Animal Medical Center, Cornell University and the Rockefeller University. At the Rockefeller University (1989 - 1992) she became specifically interested in the pathology and characterization (phenotyping) of genetically engineered mice (GEM), and continued to pursue this interest at several institutions while heading the Facility for Comparative Studies at the Hospital for Special Surgery (1992 - 1998). At Baylor College of Medicine (1998 - 2004), she headed the Comparative Pathology Laboratory, and was responsible for health surveillance and diagnostic pathology for a diverse research population, including more than 150,000 mice. She also was associate professor in pathology, associate director of the Center for Comparative Medicine, interim attending veterinarian, and served on the IACUC while pursuing research collaborations, teaching initiatives, and developing national and international conferences on the characterization and pathology of genetically engineered mice. In 2004 she moved to Johns Hokins to develop a collaborative phenotyping core based in the Department of Molecular and Comparative Pathobiology (MCB), where veterinarian faculty investigators and trainees provide a unique comparative and translational research resource, in an institution with exception resources for multidisciplinary biomedical research. She has become involved in national and international phenotyping initiatives, conferences and courses to promote understanding of mouse biology, pathology and phenotyping in contemporary preclinical translational research. 

Joseph J. DeGeorge joined Merck in 2004 as Vice President of Global Safety Assessment. Since his appointment, he has increased responsibility and has been named Global Head of Safety Assessment and Laboratory Animal Resources for Merck Research Laboratories as of September 2010 with global responsibility for non-clinical safety testing. At Merck, he has served on or chaired committees on drug discovery, drug candidate selection, early and late development, and post-marketing safety. In addition to his position with Merck, he also serves as the PhRMA Coordinator for ICH Safety Topics and has participated in development of numerous ICH Safety Guidances as a chair or member of Safety and Multidisciplinary ICH Expert Working Groups. Before working at Merck, he served as Vice President of Preclinical Safety Evaluation at Novartis Pharmaceuticals and as the Global Chair for the Research and Development Safety Assessment Committee, with responsibility for first in human studies. Prior to Novartis, he worked at the FDA from 1989 - 2002, where he was the Associate Director for Pharmacology and Toxicology in the Center for Drug Evaluation and Research (CDER) from 1996 - 2002 and was responsible for pharmacology and toxicology policy development and implementation. During his tenure at FDA he served on numerous policy and technical committees:  Chair for CDER's Carcinogenicity Assessment Committee, CDER's Pharmacology and Toxicology Coordination Committee, the preclinical lead for the FDA Genomics and Proteomics Task Force, as a member of the International Life Sciences Institute (ILSI) Risk Science Institute Threshholds Assessment Committee, the ILSI-Health and Environmental Sciences (HESI) Alternatives to Carincogenicity Testing Commitee and the ILSI-HESI Emerging Issues Committee, as CDER's technical representative to the Presidental Commission on Risk ASsessment and CDER's lead to the NIEHS-National Toxicology Program Academia, Industry and Government Partnership for the Evaluation and Validation of Transgenic Models for Carcinogenicity Testing, and as CDER's ICH Safety Coordinator and lead for many Safety Expert Working Groups. Prior to joining FDA, Dr. DeGeorge was a Senior Staff Fellow at the NIH, National Institute on Aging, Laboratory of Neurosciences, where he worked on development of in vivo functional and structural brain imaging probes. He completed his postdoctoral training as a Fellow at the University of North Carolina, Chapel Hill with a joint appointment at Burroughs Wellcome Research Institute, where he focused on neural cell to cell signaling and second messenger systems. Dr. DeGeorge received his PhD in Pharmacology from the State University of New York/Upstate Medical Center. In these various roles, Dr. DeGeorge has been responsible for implementing regulatory policies and for developing methods for reduction, refinement and replacement of animal use in biomedical research. His experience, whether in evaluating alternative methods while at FDA, or in developing new methods and gaining their regulatory acceptance and in conducting safety studies supporting pharmaceutical development, has impressed upon him the current necessity and privileged responsibility of animal use in biomedical research.

Ron DeHaven is executive vice president of the American Veterinary Medical Association (AVMA). He serves over 82,500 members of the AVMA as they work to meet the challenges of improving both human and animal health in the 21st century. Dr. DeHaven leads a staff of 140 employees and manages an operating budget of aproximately $28.5 million. The AVMA, founded in 1863, is one o fth eoldest and largest veterinary medical organizations in the world, whose members are dedicated to advancing the science and art of veterinary medicine, including its relationship to public health and agriculture. Dr. DeHaven has more than two decades of experience with the Animal Plant Health Inspection Service (APHIS). As APHIS administrator, Dr. DeHaven was ultimately responsible for the protection of U.S. agriculture and natural resources from exotic pests and diseases, administering the Animal Welfare Act, and carrying out wildlife damage management activities. Prior to being selected as APHIS administrator, Dr. DeHaven served as deputy administrator for APHIS' Veterinary Services program. Dr. DeHaven also served as acting associate administrator for APHIS from October 2001 through April 2002. From 1996 to 2001, he was the deputy administrator for the Animal Care Unit of APHIS, administering the Animal Welfare Act and the Horse Protection ACt. Before assuming the deputy administrator's position, Dr. DeHavn served as the Animal Care Unit's western regional director in Sacramento, CA for 7 years. Prior to starting work at APHIS, Dr. DeHaven was commissioned into the U.S. Army Veterinary Corps and served in the U.S. Army Reserves and National Guard. Dr. DeHaven obtained his doctor of veterinary medicine degree from Purdue University in 1975 and a master's degree in business administration from Millsaps College in 1989.

Lewis B. Kinter is currently an independent scientific consultant (Green Lawn Professional Scientific Consulting). Dr. Kinter was previously Senior Director: Regulatory Toxicology, Drug Safety and Metabolism at AstraZeneca Pharmaceuticals in Wilmington, DE and advised on preclinical safety programs conducted in support of AstraZeneca's pharmaceutical clincal development activities. Dr. Kinter has been engaged in pharmaceutical and medical device research an ddevelopment and comparative toxicology/pharmacology/physiology/medicine for over 30 years and is an internationally recognized expert in the field. Dr. Kinter received his BS in Biology at Union College (1973), and his doctorate in Medical Physiology from Harvard University (1978) where he initated his professional interests in cardiovascular/renal physiology and pharmacology. Since 1981 he has held positions of increasing responsibility in biomedical R&D with Smith Kline na dFrench, SmithKline Beecham, Sterling Winthrop, Nycomed Amersham, Astra Merck, and AstraZeneca. Dr. Kinter is a Diplomate of the American Board of Toxicology, Fellow of the Academy of Toxicological Sciences, Professor of Physiology (Adjunct) at the University of Pennsylvania School of Medicine, and has authored over 100 research manuscript snad book chapters in basic and applied physiology, pharmacology, and toxicology. He is active on the Editorial Board, Journal of Pharmacology and Experimental Therapeutics and regularly reviews research manuscripts for numerous pharmacology and toxicology journals. Dr. Kinter is currently Chair of the American Board of Toxicology (ABT), Chair of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) and Vice-Chair of the Pharmaceutical Research and Manufacturer's Association (PhRMA) Clinical and Preclinical Development Committee, and a council member of the National Academy of Sciences' Institute for Laboratory Animal Research. Dr. Kinter is a past Chair of the PhRMA Preclinical Safety Leadership committee (formerly DruSafe), PhRMA Topic Leader for the International Conference on Harmonization S10 (Phototoxicity) Expert Working Group, and a Founder and Past President of the Safety Pharmacology Scoeity and the first recipient of the Scoiety's Career Distinguished Service Award. Dr. Kinter has also held leadership positions on Boards of Directors and Trustees of local community organizations. 

Malak Kotb is a noted infectious disease and biodefense expert who was recruited in 2013 as the founding chair of the Department of Basic Sciences at the University of North Dakota School of Medicine and Health Sciences. Kotb had been a tenured professor since 2008 at the University of Cincinnati College of Medicine's Department of Molecular Genetics, Biochemistry, and Microbiology/Immunology, where she had served as chair of that department, and was also a senior career research scientist at the Cincinnati Veterans Affairs Medical Center. Prior to joining UC, she had established MidSouth Center for Emerging Infectious Diseases in Memphis, TN where she was dedicated to bolstering preparedness for natural pandemics or deliberate man-man biological attacks. At the University of Cincinnati, Kotb was a member of the Institute for Military Medicine Research in the Department of Surgery and she directed the Midwest Center for Emerging Infectious Diseases, and senior research career scientist at the Cincinnati Veteran's Affairs Hospital. Kotb earned her doctorate in immunology and biochemistry from the University of Tennessee Health Science Center and St. Jude Children's Research Hospital in Memphis. Upon completing her postdoctoral training at Howard Hughes Medical Institute at Duke University, Kotb returned to UTHSC, where she established and directed the ummunogenetics as well as the translationa and the biodefense research programs. She also founded and directed the Surgical Immunology Program for the transplant division and served as medical director for the Surgical Immunology Laboratory. Her research expertise uses interdisciplinary approaches to study the genetics and biology of disease-modifying genes and pathways. She seeks to translate her discoveries into effective diagnostic tools and effective personalized treatment for patients. Kotb holds two U.S. patents on her work in developing a medical screening method for cancer and a targeted treatment of cancer. She has chaired several national and international committees and served as a consultant and advisor to many national and international research organizations as well as global pharmaceutical companies. A 1997 Fulbright Scholar, Kotb edited two books and is the author of more than 175 original scientific articles. She participates in a number of prestigious research societies, has been invited to speak at research conferences throughout the world, and has worked on and chaired numerous grant review panels for the NIH's study sections, the Department of Veterans' Affairs, as well as for other national and international advisory boards and granting agencies. Kotb obtained her education at Cairo's American College for Girls and got her B.S. from Ain Shams University in Cairo. In 1972, she was selected by the Internatinal Rotary as a Goodwill Ambassador to the United States and was given a full scholarship to cover her education and living expenses while working toward her PhD and serving as Goodwill Ambassador between the Middle East and the U.S.

Paul A. Locke is an Associate Professor in the Department of Environmental Health Science at Johns Hopkins Bloomberg School of Public Health. He is a public health scientist and attorney with expertise in risk assessment and management, radiation protection law and policy, and alternatives to animals in biomedical testing. Dr. Locke is a member of the Board of Directors of the National Council on Radiation Protection and Measurements (NCRP) and chaired the NCRP's 2010 annual meeting program Committee. From 2004 until 2009, he was a member of the National Research Council's Nuclear and Radiation Studies Board and has participated in two NRC committees that evaluated the risks associated with the disposal of high-level radioactive waste. Dr. Locke has received several awards, including the Yale School of Public Health Alumni Service Award and the American Public Health Association Environment Section Distinguished Service Award. He holds an MPH from Yale University School of Medicine, a JD from Vanderbilt University School of Law, and a DrPH from the Johns Hopkins Bloomberg School of Public Health. He directs the EHS doctoral program in Public Health.

Daniel S. Marsman leads and manages the Product Safety Division for Procter and Gamble's worldwide Health Care and Pet care businesses, and serves as corporate veterinarian and a technical exertnal lead for P&G's Animal Alternatives and Animal Welfare programs. His interdisciplinary career has embraced the concept of 'One Health, One Medicine', beginning with his veterinary training (Michigan State University), WHO medical parasitology research in sub-Saharan Africa, his PhD in pathology from the College of Human Medicine, UNC-Chapel Hill, and his postdoctoral fellowship studying the pathobiology of neoplasia at CIIT/Hamner Institute. He has previously served as a pathologist/study scientist for the NIH's National Institute of Environmental Health Sciences, and as Head of Study Design for the NTP chronic toxicity/carcinogenicity testing program. Dr. Marsman's previous positions at P&G have included toxicological pathologist in the Human Safety department, research scientist in the carcinogensis group, and global safety/regulatory affairs manager for Household, Baby, Feminine and Family Care. He has published and consulted extensively in the fields of toxicology, pathology, animal welfare and animal alternatives. His collaborative contributions have spanned governmental, NGO and trade association technical and policy commitees, inlcuding past Chair of the Animal Welfare Committee of the AVMA, current charter diplomate in AVMA's American College of Animal Welfare, and Council Member of the National Academy of Sciences' Institute of Laboratory Animal Research.

Melinda Novak is Professor of Psychology and Chair of the Department of Psychology at the University of Massachusetts, Amherst. She received her PhD from the University of Wisconsin and accepted a faculty position at the University of Massachusetts where she established the UMass Primate Laboratory, a small primate facility in which students receive training in handling and managing captiv eprimates, performing behavioral and health assessmnts, and conducting research. She is currently the Director of this facility. Her federally funded research links four Primate Research Centers and is focused on the causes of and treatment for abnormal behavior in primates using a cross-translational model wherein monkey research informs human research and vice versa. Dr. Novak is a past President of the American Society of Primatologists and is a recent recipient of the Distinguished Primatologist Award from this society. Dr. Novak was a member of two National Academy of Sciences committees, one on Psychological Well-Being of Nonhuman Primates and the other on Recognition and Alleviation of Distress in Laboratory Animals. Dr. Novak has served on the Board of Trustees of AALAC International, the Scientific Advisory Committee of SCAW (Scientists' Center for Animal Welfare), and has also served on a number of other advisory boards, jounral editorial boards, and federal grant review panels. She was a reviewer of the updated NIH Guide to the Care and Use of Laboratory Animals and was recently selected to give the prestigious Henry J. Spira Memorial Lecture at PRIM&R. She is a current member of the Scientific Advisory Committee for the Wisconsin National Primate Center in Madison. Dr. Novak regularly reviews primate facilities and provides advice and guidance on psychological well-being programs. At the University level, Dr. Novak is a past recipient of the College Outstanding Teacher Award, the Distinguished Faculty UMass Alumni Association Award, the Award for Outstanding Accomplishments for Research and Creative Activity, an Exceptional Merit Awrad, and the Chancellor's Medal for Distinguished Faculty Lecturer, the highest honor bestowed on faculty for exemplary research and service contributions. 

James Roth is a Clarence Hartley Covault Distinguished Professor in the Department of Veterinary Microbiology and Preventitive Medicine in the College of Veterinary Medicine at Iowa State University. He received DVM (1975) and PhD (1981) degrees from ISU. He is the Director of the Center for Food Security and Public Health and the Institute for International Cooperation in Animal Biologics, an OIE Collaborating Center for Diagnosis of Animal Disease and Vaccine Evaluation in the Americas. Dr. Roth's primary area of research expertise is immunity to infectious diseases of food-producing animals. Dr. Roth received the Distinguished Veterinary Microbiologist Award from the American College of Veterinary Microbiologists, the Public Service Award from the American Veterinary MEdical Association and the USDA APHIS Administrator's Award for lifetime achievements in animal health. He has testified before Congress on biosecurity preparedness and efforts to address bioterrorism and agroterrorism. 

Lawrence Schook is Vice President for Research, encompassing the three campuses of the University of Illinois, and serves as the senior research officer of the university's $800 million/annual sponsored research portfolio, intellectual property, technology commercialization, and economic development activities. He is a noted entrepreneur who has launched two start-up medical application companies and is a Fellow at the Kaufman Academy for Entrepreneurial Leadership. He has served on the boards of multiple biotechnology companires and the board of directors for the Biotechnology Industry Organization (BIO) and was appointed by Governor to the Illinois Innovation Council. He is currently on the Board of Manager for the Argonne and Fermi National Laboratories. He is the Edward William and Jane Marr Gutgsell Professor, and previously served as the Director of the Division of Biomedical Sciences. He holds appointments as Professor of Animal Sciences, Bioengineering, Pathobiology, Nutritional Sciences, Pathology, and Surgery. He also is a Professor in the Institute for Genomic Biology and holds Affiliate Faculty appointments at the Beckman Institute for Advanced Science and Technology and the Micro and Nanotechnology Laboratory. His research focuses on comparative mammalian genomics and applications of technologies to create biomedical models. He has served as the Principal Investigator for over $25 million in sponsored research from the NIH, NSF, USDA, and industry. Professor Schook has also served in several key leadership roles a tthe National Research Council in animal genomics, and chaired the Executive Steering Committee of the Alliance for Animal Genome Research. He is the co-author of both the cattle and pig NIH genome project white papers and is Project Director for the International Swine Genome Sequencing Consortrium. He attended Albion College (BA, 1972; Distinguished Alumni Award, 1996) and received his PhD from Wayne State University School of Medicine. After postdoctoral training at the Institute for Clinical Immunology in Switzerland and the University of Michigan, he has held faculty positions at the Medical College of Virginia, University of Minnesota, and the Ludwig Cancer Center at the University of Lausanne. 

Sheldon Sloan joined Janssen Pharmaceutica, a subsidiary of Johnson and Johnson in 1997. He has served in numerous roles within Janssen and Johnson & Johnson, including a leadership role in Medical Affairs for Gastroenterology and CNS. He has had several core R&D positions including Medical Director, Team Leader, and lead presenter at two FDA Advisory Committee meetings. Dr. Sloan's interest in bioethics was a result of his experiences as Vice President of Policy in the J&J Corporate Office of Science and Technology, a position he held for 6 years. During his tenure there, he helepd launch a corporate-wide 3R's awareness program, instituting a research award with dedicated funds for a 3R's project and recognition for novel 3R's approaches. Before joining J&J, Dr. Sloan was an Assistant Professor of Medicine at Rush Medical College and the director of the Gastrointestinal Motility Laboratory at Rush Medical Center in Chicago. He is the recipient of the 1991-1993 Glaxo Institute for Digestive Health Clinical Research Award, and his memberships include the American College of Gastroenterology, the American College of Physicians, the American Gastroenterological Association, and the American Society for Bioethics and Humanities. He has authored numerous publications for peer-reviewed journals and book chapters. Dr. Sloan received his medical degree from Rush Medical College in Chicago, and completed a residency in internal medicine and a fellowship in clinical gastroenterology at Rush-Presbyterian-St. Luke's Medical Center. He then completed a research fellowship in gastrointestinal motility at Northwestern University Medical School in Chicago. Dr. Sloan received his Msaters of Bioethics from the University of Pennsylvania. 

Patricia Turner is a Professor in the Department of Pathobiology and Program Leader of graduate studies in Laboratory Animal Science at the University of Guelph. She also manages the campus laboratory animal diagnostic pathology core and provides consultative laboratory animal pathology services. Her research interests include infectious diseases of laboratory animals, the influence of environment on roden affective state, and anesthesia, alagesia, andeuthanasia of laboratory animals. She holds a BSc in Biochemistry from McMaster University, an MSc in Pharmacology from Dalhousie University, a DVM from the Ontario Veterinary College, and a DVSc in Comparative Pathology from the University of Guelph. Following post-doctoral work at McGill University, she worked as Director of Animal Care Services and Assistant Professor of Pathology at Queen's University. She later worked for Warner-Lambert an dPfizer as a toxicology team represntative in preclinical safety testing. Turner teaches laboratory animal medicine and pathology, animal welfare, and toxicologic pathology at the University of Guelph and is a Diplomate of the American College of Laboratory Animal Medicine (ACLAM), the American Board of Toxicology (ABT), and the European College of Animal Welfare and Behavioral Medicine (ECAWBM). She is currently the President of the International Association of Colleges of Laboratory Animal Medicine (IACLAM), a Councilor for the World Veterinary Association (WVA), anda Council Member for the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC).